MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Milestone Pharmaceuticals Inc (MIST) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, the options data shows weak sentiment, and the company's financial performance is poor with consistent losses. Additionally, analysts have downgraded the stock to a 'Sell' rating, and there are no strong positive catalysts to justify an investment.
The technical indicators for MIST are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral but low at 22.38, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 1.199 and resistance at 1.458.
The company has announced plans for a Phase 3 program for Etripamil, which could be a long-term growth driver if successful.
The company reported a net loss of $17.4 million in Q4 2025 and a full-year loss of $63.1 million. Analysts have downgraded the stock to a 'Sell' rating following poor financial performance. Additionally, the stock's technical indicators and options data do not support a bullish outlook.
In Q4 2025, the company reported $1.55 million in revenue, which remained flat YoY. Net income improved to -$17.4 million, up 40.82% YoY, but EPS dropped to -$0.16, down 15.79% YoY. The company continues to operate at a loss, and its financials do not indicate strong growth potential.
Analysts have downgraded the stock to a 'Sell' rating following the company's poor financial performance and limited revenue growth.
